Development of the multi-target-directed acetylcholinesterase inhibitors based on tacrine

Chinese Pharmacological Bulletin

Volumn 24, Issue 12, 2008, Pages 1549-1554

  Ye, Min Zhong ^a   Cheng, Zhi Yi ^a   Pi, Rong Biao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Lacrine; Multi target

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DIHYDROPYRIDINE; DONEPEZIL; GALANTAMINE; GALLAMINE; HETERODIMER; HUPERZINE A; HUPRINE X; HUPRINE Y; MELATONIN DERIVATIVE; NITRIC OXIDE DONOR; NOOTROPIC AGENT; RIVASTIGMINE; SEROTONIN 3 ANTAGONIST; TACRINE DERIVATIVE; THIOCTIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DRUG ACTIVITY; DRUG BINDING SITE; DRUG DESIGN; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME MODIFICATION; IC 50; NEUROFIBRILLARY TANGLE; NONHUMAN; SENILE PLAQUE; STRUCTURE ACTIVITY RELATION;

EID: 60749136418     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kathryn Z G, Ron Brookmeyer, Elizabeth J,et al. Worldwide variation in the doubling time of Alzheimer' s disease incidencerates. Alzheimer's and Dementia [J], 2007,3(3):S168-S169.
2. Cavalli A, Bolognesi M L, Minarini, et al. Multi-target-directed ligands to combat neurodegenerative diseases[J]. J Med Chem, 2008,51(3):347-72.
3. Wang H, Carlier P R, Ho W L,et al. Effects of bis(7) -tacrine, a novel anti-Alzheimer's agent, on rat brain AChE [J]. NeuroReport, 1999, 10(4):789-93.
4. Pan S Y, Han Y F, Carlier P R, et al. Schisandrin B protects against tacrine- and bis(7)-tacrine-induced hepatotoxicity and enhances cognitive function in mice[J]. Planta Med, 2002, 68 (3):217-20.
5. Li W, Pi R B, Chan H H,et al, Novel dimeric acetylcholinesterase inhibitor bis7-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors [J]. J Biol Chem, 2005,280(18):79-88.
6. Luo J, Li W, Liu Y, et al. Novel dimeric his (7 -tacrine proton-dependently inhibits NMDA-activated currents [J]. Biochem Biophys Res Commum, 2007,361(2):505-9.
7. Fu H J, Li Wm, Luo J L, et al. Promising anti-Alzheimer' s dimer bis (7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity[J]. Biochem Biophys Res Commum, 2008 15, 366(3):631-6.
8. Hu M K, Wu L J, Hsiao G, et al. Homodimeric tacrine congeners as acetylcholinesterase inhibitors [J]. J Med Chem, 2002, 45 (11):2277-82.
9. Savini L, Campian G, Gaeta A, et al Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase[J]. Bioorg Med Chem Lett, 2001, 11(13): 1779-82.
10. Carlier P R,Du D M, Han Y,et al. Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors[J]. Bioorg Med Chem Let, 1999, 9(16): 2335-8.
11. Shao D, Zou C, Luo C, et al. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer' s disease [J]. Bioorg Med Chem Lett, 2004, 14 (18): 4639-42.
12. Martinez A,Dorronsoro I,Rubio L,et al. Dual binding site acetylcholinesterase inhibitors for the treatment of Alzheimer' s disease. WO 2004032929 [P]. http://www.wipo.int.
13. Lewis W G, Green L G, Grynszpan F, et al. Click Chemistry in situ: Acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibtor from an array of building blocks[J]. Angew Chem Int Ed2002,41(6):1053-7.
14. Krasinski Q, Radic Z, Manetsch R, et al. In situ selection of lead compounds by click chemistry: target-guided optimization of Acetylcholinesterase inhibitors[J]. J Am Chem Soc,2005,127(18): 6686-92.
15. Camps P, Muñoz T D, Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer' s disease. Mini-Rev[J]. Med Chem, 2001,1(2):163-74.
16. Badia A, Baños J E, Camps P, et al. Synthesis and evaluation of tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease [J]. Bioorg Med Chem, 1998, 6(4):427.
17. Camps P, Gomez E, Munoz-Torrero D, et al. Synthesis, in vitro pharmacology, and molecular modeling of syn huprines as acetylcholinesterase inhibitors[J]. J Med Chem,2001,44(26):4733-6.
18. Camps P, Formosa X, Muñoz-Torrero D, et al. Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: sub-nanomolar dual binding site acetylcholinesterase inhibitors[J]. J Med Chem, 2005,48(6):1701-4.
19. Michela R, Vincenza A, Manuela B, et al. Rational Approach To Discover Multipotent Anti-Alzheimer Drugs [J]. J Med Chem, 2005, 48(2):360-3.
20. Rodriguez FM, Fernandez MI, Perez C, et al. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties [J]. J Med Chem,2006,49(2):459-62.
21. Fang L, Kraus B , Lehmann J, et al. Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates[J]. Bioorg Med Chem Lett,2008,18(9):2905-9.
22. 2+ channelsand nicotinic receptors[J]. Bioorg Med Chem, 2004,12(9):2199-218.
23. Andrea C, Andrea G, Monica M, et al. Further studies on the interaction of the 5-Hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties[J]. J Med Chem,2005, 48(10):3564-75.
24. Bolognesi M L, Cavalli A, Valgimigli L, et al. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer' s disease [J]. J Med Chem,2007,50(26):6446-9.
25. Fang L, Appenroth D, Decker M,et al. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates [J]. J Med Chem, 2008,51(4):713-6.
26. Elsinghorst P W, Cieslik J S, Mohr K, et al. First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor[J]. J Med Chem, 2007,50(23):5685-95.